


- Nemiralisib is currently in development for the treatment of chronic obstructive pulmonary disease (COPD).
- It selectively inhibits the delta isoform of phosphatidylinositol-3-kinase which has been implicated in potentiating the inflammatory response to allergens in the airways.
- The initial supply route was used to generate 5 kg of material for Phase I clinical studies.




Wheelhouse, K. *Org. Process Res. Dev.* **2021**  
<https://doi.org/10.1021/acs.oprd.0c00486>

## Initial Route:



Huisgen, R. J. *Lieb. Ann. Chem.* **1954**, 586, 84 <https://doi.org/10.1002/jlac.19545860106>

## New Strategy:



## Final Process Route:

